VERTEX PHARMACEUTICALS INC (VRTX)

Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?

3 Fantastic Stocks That Could Enjoy a Santa Claus Rally

3 Fantastic Stocks That Could Enjoy a Santa Claus Rally

Santa Claus will soon be on his way delivering presents to kids around the world. Three Motley Fool contributors think they've identified fantastic stocks that could be in a good position to benefit from a Santa Claus rally. Here's why they chose AbbVie (NYSE: ABBV), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX).

My Top 10 Stocks to Buy for 2025

Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock

The FDA signed off on Vertex's newest cystic fibrosis treatment. But it might not help beleaguered Vertex stock.

Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants

Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.

Unusual volume S&P500 stocks in Friday's session

What's going on in today's session: S&P500 movers

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Friday as we examine the latest happenings in today's session.

Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review

Micron, Vertex, Novo Nordisk and Nike were notable losers on news.

Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Friday. Discover the gap up and gap down stocks in the S&P500 index.

Let's have a look at the S&P500 gap up and gap down stocks in today's session.

Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?

The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.

What's going on in today's session: S&P500 movers

Thursday's session: top gainers and losers in the S&P500 index

Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?

On Thursday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the lower back and hip that radiates down the back of the thigh into the leg. The study met its primary endpoint with a statistically significant and clinically meaningful reduction in pain on the numeric pain rating scale (NPRS). The suzetrigine arm showed a statistically significant and clinically mean

In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Thursday's session.

In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Thursday's session.

Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.

Thursday's session: top gainers and losers in the S&P500 index

Vertex Pharmaceuticals is Now Oversold (VRTX)

Which S&P500 stocks are gapping on Thursday?

These S&P500 stocks are gapping in today's session

Nasdaq 100 Movers: MU, MRVL

Vertex Plunges 10% After Its Non-Opioid Pain Drug Flops In Lower Back Pain

The company says there was variability among placebo responses at various sites.

What's going on in today's pre-market session: S&P500 movers

Top S&P500 movers in Thursday's pre-market session

Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging.

Vertex Pharmaceuticals' drug reduced back pain significantly.

Vertex’s Opioid Alternative Meets Goal in Back Pain Trial

Vertex Pharmaceuticals Inc.’s non-addictive drug helped patients with lower back pain, moving the company closer to selling an alternative to opioids in another type of pain.

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy

2 Unstoppable Stocks to Buy and Hold for the Next Decade

Notable Wednesday Option Activity: JPM, MCD, VRTX

2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?

Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030

3 Unstoppable Stocks to Buy Right Now

The Ultimate Biotech Stock to Buy With $500 Right Now

Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock

Jefferies has upgraded Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), citing the company’s robust cystic fibrosis base business and the additional upside from the new LNP/ mRNA therapy (around $1 billion opportunity) and “triple pill” regimens. The company’s pipeline can potentially exceed expectations if the data is positive. The analyst views the risk/reward balance as mostly neutral for 2024. The pain program stands out as a potential blockbuster, especially with the upcoming launch for acute pai

2 No-Brainer Stocks to Buy Before the End of 2024

Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update

3 No-Brainer Growth Stocks to Buy in December

3 No-Brainer Growth Stocks to Buy in December

It's what most investors want more than anything else from their stocks. Three Motley Fool contributors think they've identified no-brainer growth stocks in the healthcare sector to buy in December. Here's why they picked Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX).

Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?

Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?

The company is still suffering from the significant drop in sales of its coronavirus products and the less-than-impressive financial results it has produced during the past two years. Pfizer has, unquestionably, made progress. Many new approvals and acquisitions have expanded its lineup and pipeline.